Clinical stage biopharmaceutical company: Provention Bio, Inc. (PRVB)

Provention Bio, Inc. (NASDAQ:PRVB) was founded in 2016 and is headquartered in Oldwick, New Jersey, USA. Among them, there are about 7 people. It is a clinical-stage biopharmaceutical company focusing on the development and commercialization of new therapies, as well as interception and prevention Cutting-edge solutions for immune-mediated diseases.

Provention Bio

Provention Bio, Inc. (PRVB):

Provention Bio, Inc. It is a clinical stage biopharmaceutical company that aims to develop new therapies to intercept and prevent immune-mediated diseases. The company uses a transformational drug development strategy to find, reposition and advance candidate products:

  • Interception or prevention of immune-mediated diseases
  • Insufficient clinical trial efficacy or abandoning development or lowering priority for strategic reasons
  • Prove the pharmacological mechanism by preventing or blocking immunopathological pathways

Candidate products include:

  • PRV-031 teplizumab and monoclonal antibody (mAb): for the interception of type 1 diabetes (T1D), currently in phase III clinical stage.
  • PRV-6527, an oral CSF-1R inhibitor, is currently in phase IIa clinical trials for the treatment of Crohn’s disease.
  • PRV-300, an anti-TLR3 mAb, is currently in phase Ib clinical trials for the treatment of ulcerative colitis.
  • PRV-3279, used to treat lupus.
  • PRV-101, a multivalent Coxsackie virus vaccine, is used to prevent acute Coxsackie virus B vaccine and prevent the onset of T1D.

Provention Bio and Amgen Inc. signed a licensing and co-development agreement for AMG 714.

Stock price changes:

On June 10, 2019, Provention Bio rose more than 300% in the intraday market, as it announced that the drug candidate teplizumab (PRV-031) had positive trial data and was used to intercept type 1 diabetes (T1D) in Phase III development).

Provention Bio, Inc. (PRVB) investment:

Provention Bio, Inc. (NASDAQ:PRVB) was listed on NASDAQ on 7/24/2018 IPO, with an issue price of US$4, 16,375,000 shares, and US$65.5 million in capital.

Notify of
Inline Feedbacks
View all Intels

Diversified printing company: Ceveo (CVO) (1991)

The largest investment management company in the United States: BlackRock (BLK) (1988)